Printer Friendly

New market study, "Global Cephalosporin Drugs Market 2015-2019", has been published.

[USPRwire, Tue Nov 10 2015] Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into "generations" by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.

Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

Full Report Details at

- http://www.fastmr.com/prod/1055041_global_cephalosporin_drugs.aspx?afid=302

Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

* Americas

* APAC

* EMEA

Key vendors

* Allergan

* Astellas

* Bristol-Myers Squibb

* GlaxoSmithKline

* Merck

* Pfizer

* Sandoz

* Teva Pharmaceuticals

Other prominent vendors

* Abbott

* Aspen Pharmacare

* AstraZeneca

* Aurobindo Pharma

* Basilea Pharmaceuticals

* Baxter

* Biocon

* Corden Pharma

* Cornerstone Therapeutics

* Eli Lilly

* F. Hoffmann-La Roche

* Flynn Pharma

* Hospira

* Incepta Pharmaceuticals

* Johnson & Johnson

* Kyorin Pharmaceutical

* Lupin Pharmaceuticals

* Orchid Pharma

* Par Pharmaceutical

* Pernix Therapeutics

* Sanofi

* Shionogi

* Sun Pharmaceutical

* Takeda Pharma

* Theravance Biopharma

* Wockhardt

Market driver

* Special regulatory designation for pipeline molecules

* For a full, detailed list, view our report

Market challenge

* Development of drug resistance

* For a full, detailed list, view our report

Market trend

* Use of combination therapies

* For a full, detailed list, view our report

Key questions answered in this report

* What will the market size be in 2019 and what will the growth rate be?

* What are the key market trends?

Copyright [c] 2015 USPRwire Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:USPRwire
Date:Nov 10, 2015
Words:374
Previous Article:Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2015 - New Study Released.
Next Article:The Global Maritime and Border Security Market 2015-2025 - Market Size and Drivers: Market Profile.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters